Financial Advisory Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-986
Closed -$229K 67
2025
Q3
$229K Buy
+986
New +$201K 0.07% 67
2025
Q2
Sell
-1,411
Closed -$296K 67
2025
Q1
$296K Sell
1,411
-125
-8% -$24.3K 0.1% 61
2024
Q4
$273K Buy
1,536
+172
+13% +$31.6K 0.09% 62
2024
Q3
$270K Sell
1,364
-210
-13% -$39.2K 0.09% 64
2024
Q2
$270K Hold
1,574
0.1% 62
2024
Q1
$287K Hold
1,574
0.11% 61
2023
Q4
$244K Hold
1,574
0.09% 61
2023
Q3
$235K Hold
1,574
0.09% 62
2023
Q2
$212K Hold
1,574
0.08% 63
2023
Q1
$251K Sell
1,574
-97
-6% -$14.8K 0.1% 62
2022
Q4
$270K Sell
1,671
-28
-2% -$4.29K 0.11% 62
2022
Q3
$228K Sell
1,699
-25
-1% -$3.59K 0.1% 63
2022
Q2
$264K Buy
1,724
+95
+6% +$14.5K 0.11% 63
2022
Q1
$264K Sell
1,629
-167
-9% -$24.3K 0.1% 65
2021
Q4
$243K Buy
+1,796
New +$212K 0.09% 68

Other funds holding ABBV

Financial Advisory Partners's ABBV Position: Q4 2025 in Review

Financial Advisory Partners sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 986 shares — an estimated $229K sold.

Financial Advisory Partners first reported a position in ABBV in Q4 2021 and held it in 15 quarters. The position peaked at $296K in Q1 2025. 4,155 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Financial Advisory Partners reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
  • Financial Advisory Partners sold 986 AbbVie shares in Q4 2025, an estimated $229K.
  • Financial Advisory Partners first reported a position in AbbVie in Q4 2021 and held it in 15 quarters.
  • Financial Advisory Partners's AbbVie position peaked at $296K in Q1 2025.
  • 4,155 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Financial Advisory Partners's 13F filing for Q4 2025, filed 23 Jan 2026.